Cargando…
Distal muscle weakness is a common and early feature in long-term enzyme-treated classic infantile Pompe patients
BACKGROUND: Enzyme replacement therapy (ERT; alglucosidase alfa) has improved the prospects for patients with classic infantile Pompe disease considerably. However, over time we noticed that many of these children exhibit distal muscle weakness at an early age, which is in contrast to the primarily...
Autores principales: | van den Dorpel, J. J. A., Poelman, E., Harlaar, L., van Kooten, H. A., van der Giessen, L. J., van Doorn, P. A., van der Ploeg, A. T., van den Hout, J. M. P., van der Beek, N. A. M. E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488760/ https://www.ncbi.nlm.nih.gov/pubmed/32928284 http://dx.doi.org/10.1186/s13023-020-01482-w |
Ejemplares similares
-
Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long‐term clinical outcome of classic infantile Pompe patients
por: Poelman, Esther, et al.
Publicado: (2020) -
Neurofilament Light and Its Association With CNS Involvement in Patients With Classic Infantile Pompe Disease
por: Mackenbach, Maarten J., et al.
Publicado: (2023) -
Effects of immunomodulation in classic infantile Pompe patients with high antibody titers
por: Poelman, E., et al.
Publicado: (2019) -
Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy
por: van Gelder, C. M., et al.
Publicado: (2011) -
Diffusion tensor imaging of the brain in Pompe disease
por: van den Dorpel, Jan J. A., et al.
Publicado: (2022)